Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 5, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Kidney CancerRenal Cell CarcinomaMetastatic Renal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

Doppler Ultrasound

Power Doppler measurements will be made

DEVICE

SIEMENS S3000 and Verasonics Vantage 256

Vantage 256 used for power Doppler ultrasound, manufactured by Verasonics

DRUG

Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)

Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI).

DRUG

Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI

Standard-of-care non-immune checkpoint inhibitor (ICI) such as single-agent VEGFR2 TKI

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Stanford University

OTHER

NCT04508725 - Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) | Biotech Hunter | Biotech Hunter